NASHVILLE, TENNESSEE / ACCESS Newswire / November 20, 2025 / CenExel, a leading network of clinical research sites, is hosting a two-day Good Clinical Practice (GCP) training initiative beginning today, November 20, 2025, at the Sheraton Grand Nashville. Nearly 80 attendees, including Principal Investigators, sub-Investigators, regulatory and quality professionals, and clinical operations leaders, have gathered to enhance their understanding of the core regulatory and ethical standards that underpin every CenExel trial.
The training is facilitated by Deb Autor, JD, Elvira Cawthon, BS, MS, EMT-P, and Thom Mezak, MBA, PMP of Healthcare Innovation Catalysts, experts with extensive experience in regulatory compliance, data integrity, and investigator oversight. “Clinical research is rapidly evolving, but the core fundamental principles of GCP are still critical,” said Deb, who is also a former FDA Deputy Commissioner. “By prioritizing this level of rigorous, hands-on training, CenExel is aiming to strengthen its future, elevating the quality of its trials and ensuring that every partner and patient can trust the work being done across the network.”
Over the next two days, participants will explore key GCP principles, including ALCOA+++ data integrity, ICH GCP guidelines, and FDA and IRB regulations governing investigator responsibilities. The agenda also includes deep dives into Principal Investigator oversight, protocol compliance, adverse event reporting, and documentation standards, all of which are critical to maintaining the highest quality and ethical standards in clinical research.
“At CenExel, we hold ourselves to the highest level of scientific and regulatory excellence,” said Ryan Brooks, CenExel’s Chief Executive Officer. “This training reinforces our shared responsibility to sponsors, CROs, and – most importantly – our patients, ensuring that every study we conduct meets the highest standards of data integrity and participant safety.”
Hollie DeSmet, Vice President of Regulatory & Quality Assurance at CenExel, also emphasized the importance of this endeavor by saying, “The Good Clinical Practice training underscores our unwavering commitment to regulatory compliance and quality assurance across the CenExel network. By investing in rigorous education for our investigators and operational teams, we reinforce the integrity of our research processes and safeguard the trust placed in us by sponsors and patients. This initiative ensures that every study we conduct adheres to the highest ethical and scientific standards, advancing our mission to deliver reliable data and improve patient outcomes.”
Building on this foundation, the GCP training reflects CenExel’s broader investment in staff development, operational consistency, and collaboration across its nationwide network of Centers of Excellence. By aligning investigators and quality professionals under a shared framework of compliance and best practices, CenExel strengthens its ability to deliver high-quality data and reliable results to its partners, supporting the company’s mission to accelerate the development of new treatments through precise execution, trustworthy data, and the highest ethical standards.
Contact Information
Sara Koeblin Director of Corporate Communications s.koeblin@cenexel.com (617) 639-6075
Leading Regina clinic recognized for delivering timely, accurate MRI services with a patient-first approach.
REGINA, SASKATCHEWAN / ACCESS Newswire / November 20, 2025 / Open Skies MRI, a trusted leader in advanced diagnostic imaging, has won the 2025 Consumer Choice Award in the Diagnostic Imaging Clinics category for Regina. For the past 7 years this recognition has underscored Open Skies MRI’s dedication to delivering timely, accurate imaging services in a patient-first environment that prioritizes comfort and confidence.
Since 2012, Open Skies MRI has provided residents across Regina and Saskatchewan with access to high-quality MRI scans supported by clear communication and fast results. Patients and referring physicians rely on the clinic’s combination of modern technology and compassionate care to guide important health decisions.
Expert Diagnostic Care Close to Home Open Skies MRI was founded to address a simple but vital need: more timely access to diagnostic imaging for Saskatchewan residents. By offering private MRI services, the clinic gives patients an alternative to long wait times, helping them get answers sooner and start treatment without unnecessary delays.
“Receiving the Consumer Choice Award once again reflects the confidence that patients and physicians place in our team’s commitment to timely, accurate, and patient-focused diagnostic imaging,” said Cam Barrett, Chief Executive Officer at Prairie Skies Medical Imaging. “Our priority is to ensure every patient feels informed and supported throughout their experience with us.”
Fast, Comfortable, and Accurate Patients choose Open Skies MRI not only for its advanced equipment but for the experience itself. The clinic ensures that each visit is as smooth and stress-free as possible through:
Timely Appointments: Faster booking and results mean less waiting and worry.
Clear, Precise Images: High-resolution scans help physicians make informed diagnoses.
Patient Comfort: Friendly staff, clear explanations, and a welcoming environment help ease anxiety.
Seamless Physician Collaboration: Detailed reports are sent promptly to referring doctors, ensuring continuity of care.
This commitment to service has made Open Skies MRI a trusted partner in the region’s healthcare system.
Putting Patients First Every member of the Open Skies MRI team understands that diagnostic imaging can feel intimidating. That’s why they prioritize education and compassion at every step – answering questions thoroughly, explaining procedures in plain language, and ensuring patients know what to expect before, during, and after their scan.
The result is a diagnostic experience that feels supportive and reassuring rather than rushed or impersonal.
A Community Partner in Health Locally owned and operated, Open Skies MRI is proud to play a vital role in Regina’s health landscape. The clinic has built strong relationships with the Saskatchewan Health Authority, local physicians, specialists, and patients, earning a reputation for quality care delivered with integrity and respect. This dedication has earned Open Skies MRI the Consumer Choice Award for seven consecutive years – a testament to their consistent focus on trusted results and patient satisfaction.
Word-of-mouth referrals and positive patient stories continue to drive the clinic’s growth and reinforce its mission: to make top-tier diagnostic imaging accessible to everyone who needs it.
Continuing to Raise the Standard With this Consumer Choice Award, Open Skies MRI has continued investing in newest imaging technologies and expanded imaging capacity to meet growing demand.
For more information about Open Skies MRI or to schedule an appointment, CLICK HERE or visit www.openskies.ca.
About Consumer Choice Award Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category win this prestigious recognition. Visit www.ccaward.com to learn more.
Contact Information Sumi Saleh Communications Manager ssaleh@ccaward.com
Capital will fuel product development, hiring, and expansion into large-scale manufacturing
SAN FRANCISCO, CA / ACCESS Newswire / November 20, 2025 / Parallax Worlds, the company building hyper-realistic simulations to stress-test robots before deployment, today announced a $4 million seed round, bringing total pre-seed and seed funding to $4.9 million. The round was led by Pear VC, with participation from GS Futures, Kakao Ventures, and Lightscape Partners, alongside angels and groups including Gaingels, Nova Threshold, and Mana Ventures. Prior backers include Conviction (Embed), Unusual Ventures, Spacecadet Ventures (co-leads of the pre-seed), and Boost VC.
Modern factories and warehouses want to adopt robots to meet reshoring goals and close labor gaps, but getting from pilot to production is slow, expensive, and risky. Even simple automation projects can take a year and require extensive on-site testing to achieve the uptime and reliability that production lines demand. Parallax Worlds eliminates that bottleneck by letting robotics builders and operators exhaustively test, measure, and validate performance in a high-fidelity digital twin before any hardware touches the floor.
“Production-grade reliability is the gap between a great demo and a great deployment,” said Tanmay Agarwal, Co-founder & CEO, Parallax Worlds. “Factories can’t afford robots that fail even for seconds; they need reliable performance and defensible ROI. Parallax Worlds gives builders and operators a way to measure reliability upfront, compress on-site iteration, and move from pilot to production faster.”
Parallax Worlds’ vertically integrated platform turns simple video capture (e.g., an iPhone walkthrough) into an accurate, interactive 3D environment. Today, teams can generate fully navigable digital twins from video and run interactive simulations using real robot software. The platform is actively expanding to support cloud-scale execution of thousands of edge-case scenarios and to deliver automated reliability, cost, and ROI metrics tied to specific tasks and site conditions. It integrates with industry physics engines and tooling (e.g., NVIDIA Omniverse, Unreal, Unity) while adding the missing layers, including fast video-to-3D, robotics-specific behaviors, and AI-assisted scenario generation.
“Parallax is building the missing simulation layer that bridges robotics R&D and real-world deployment by virtualizing physical spaces to make testing and reliability scalable,” said Payam Banazadeh, Visiting Partner, Pear VC. “Their digital-twin platform turns simulation into a true reliability engine, transforming what used to take years of costly trial and error into weeks of virtual iteration. It’s the kind of foundational shift that will redefine how entire industries build and trust automation, and we’re proud to back the Parallax team as they make this vision a reality.”
The company is led by a founding team with deep roots in both advanced robotics and industrial automation. Agarwal trained in Stanford’s robotics community under Prof. Fei-Fei Li and Prof. Jiajun Wu, and has developed software for systems ranging from home robots to self-driving vehicles. Aumkar Renavikar, Co-Founder and CTO, studied robotics at UIUC and supported factory-floor automation initiatives at BMW and Michelin, grounding the company’s approach in real industrial requirements.
The company has signed multiple robotics companies across manufacturing, construction, and select consumer-service use cases, including Orangewood Labs (industrial robots for manufacturing), BotBuilt (robots for home construction), and Rainier Labs (mobile welding robots).
“Parallax lets us validate robot behavior against real factory conditions using our actual control software,” said Abhinav Das, CEO at Orangewood Labs. “Being able to iterate on perception, planning, and edge-case handling before hardware is deployed materially accelerates our development cycle.”
With the new round, the company will expand into large enterprise manufacturing, while continuing to grow within its robotics-builder customer base. Funds will be used for product R&D, hiring, and go-to-market.
Reshoring and American dynamism demand more automation, but today only the largest manufacturers can shoulder the cost and time of traditional deployment cycles. By shifting reliability testing into a realistic virtual environment, Parallax Worlds aims to democratize access to robotics, enabling more factories and warehouses to adopt automation with confidence.
Parallax Worlds provides hyper-realistic simulation software to stress-test robots before deployment. The company’s platform transforms everyday video into high-fidelity digital twins and runs cloud-scale simulations with robotics-specific behaviors and AI-generated scenarios, delivering reliability, safety, and ROI insights before hardware hits the factory floor. Parallax Worlds is headquartered in San Francisco. Learn more at parallaxworlds.com.
FRISCO, TEXAS / ACCESS Newswire / November 20, 2025 / GameSquare Holdings, Inc. (“GameSquare” or the “Company”) a next-generation media, entertainment, technology and digital native treasury company, today announced it repurchased 1,120,606 shares of its common stock for $565,806, representing an average price of approximately $0.50 per share. Following this transaction, the Company has approximately $3.9 million remaining under its current authorization.
Consistent with its capital allocation priorities, GameSquare intends to continue to opportunistically repurchase its common stock. Since October 2025, the Company has repurchased a total of 1,953,730 shares of its common stock for $1,164,955, representing an average price of approximately $0.60 per share.
“GameSquare has never been in a stronger financial and operating position,” said Justin Kenna, CEO of GameSquare. “At current share prices, we see a compelling dislocation between our intrinsic value and market value, and we will continue to allocate capital to opportunistic repurchases where we believe it meaningfully enhances shareholder value. This buyback is a clear signal of that conviction and the strength of our business model.”
About GameSquare Holdings, Inc. GameSquare (NASDAQ:GAME) is a cutting-edge media, entertainment, and technology company transforming how brands and publishers connect with Gen Z, Gen Alpha, and Millennial audiences. With a platform that spans award-winning creative services, advanced analytics, and FaZe Clan Esports, one of the most iconic gaming organizations, we operate one of the largest gaming media networks in North America. As a digital-native business, GameSquare provides brands with unparalleled access to world-class creators and talent, delivering authentic connections across gaming, esports, and youth culture. Complementing our operating strategy, GameSquare has developed an innovative treasury management program designed to generate yield and enhance capital efficiency, reinforcing our commitment to building a dynamic, high-performing media company at the intersection of culture, technology, and next-generation financial innovation.
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company’s future performance, returns generated by its business strategies, revenue, growth and profitability; and the Company’s ability to execute on its current and future business plans. These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company’s ability to grow its business and being able to execute on its business plans and strategies, the success of Company’s vendors and partners in their provision of services to the Company, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to support its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company’s annual meeting and corporate governance, its ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company’s portfolio across entertainment and media platforms, dependence on the Company’s key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company’s most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Corporate Contact Lou Schwartz, President Phone: (216) 464-6400 Email: ir@gamesquare.com
Investor Relations Andrew Berger Phone: (216) 464-6400 Email: ir@gamesquare.com
Media Relations Chelsey Northern / The Untold Phone: (254) 855-4028 Email: pr@gamesquare.com
Las Vegas, NV – November 20, 2025 – PRESSADVANTAGE –
Press Advantage announced today that an independent analysis of its press release distribution network demonstrates that each distributed release generates backlinks with an equivalent market value exceeding $68,000 when compared to standard guest posting rates. The analysis examined the quantity and domain authority of backlinks created through the company’s distribution network.
The study evaluated backlink generation across Press Advantage’s network of news outlets, which includes ABC, NBC, CBS, and FOX affiliates, along with digital platforms such as Yahoo!, Digital Journal, and regional newspapers including the Boston Globe and Miami Herald. The analysis found that a single press release distribution typically generates between 200 to 400 backlinks from news sites with domain authority scores ranging from 40 to 90.
Based on current market rates for guest posting services, which range from $200 to $500 per placement on comparable domain authority sites, the total value of backlinks generated through one press release distribution exceeds $68,000. This calculation reflects standard industry pricing for acquiring individual backlinks through traditional outreach methods.
“The analysis examined actual link generation data from our platform and compared it against prevailing market rates for similar domain authority placements,” said Jeremy Noetzelman, CEO of Press Advantage. “The data shows that businesses receive placement on hundreds of news sites through a single distribution, creating backlinks that would require significant investment to acquire individually through guest posting services.”
The Press Advantage Company Profile indicates the service has distributed content for over 16,672 businesses since 2013. The platform combines press release writing with distribution to create indexed pages across multiple media properties. Each placement generates a backlink from the hosting news site, with these links remaining active indefinitely as permanent digital assets.
The analysis methodology involved documenting the number of successful placements from sample distributions, recording the domain authority of each placement site, and calculating equivalent costs based on publicly available guest posting rate cards from link building services. News outlets in the distribution network maintain domain authority scores that search engines recognize as indicators of site credibility and trust.
Press Advantage Helping Local Businesses in SEO through its distribution model creates what the analysis describes as a network effect, where multiple placements across varied media properties establish a distributed digital footprint. This approach differs from traditional link building methods that typically focus on securing individual placements through manual outreach.
The platform’s premium distribution options add financial newswires including Yahoo! Finance and NASDAQ to the standard distribution list. These financial news placements carry domain authority scores at the higher end of the spectrum due to their editorial standards and verification processes.
The backlink analysis represents a snapshot of current market conditions and pricing structures in the link building industry. Guest posting rates vary based on factors including domain authority, traffic metrics, and niche relevance. The $68,000 valuation reflects aggregate value based on individual placement costs rather than bulk purchasing arrangements.
Press Advantage operates as part of Velluto Tech Incubator, a software development company established in Las Vegas, Nevada in 2011. The organization develops cloud-hosted solutions for online visibility and customer acquisition. The platform provides press release writing and distribution services, with additional information available at pressadvantage.com.
###
For more information about Press Advantage, contact the company here:
Press Advantage Jeremy Noetzelman support@pressadvantage.com PO Box 29502 #84699 Las Vegas, NV 89126
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026
Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028
Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene
Further improves 2026 and 2027 expected GAAP operating expenses by approximately $0.5 billion each year on path to targeted cash breakeven in 2028
CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced program and financial updates at its Analyst Day event. The updates include mRNA pipeline progress and a three-year plan for strategic growth.
“Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics,” said Stéphane Bancel, CEO of Moderna. “We plan to deliver up to 10 percent revenue growth in 2026 while continuing to reduce our R&D investments and diversify further into oncology. Our financial outlook remains strong, and we are focused on disciplined execution as we advance our pipeline and bring innovative mRNA medicines to patients around the world.”
Business Strategy & Commercial Growth Drivers
Over the near term, Moderna will continue to build a large seasonal vaccine franchise targeting at-risk populations and propelling the Company to 2028 cash breakeven. The Company expects to invest the cash generated from its marketed products, Spikevax®, mRESVIA® and mNEXSPIKE®-as well as from anticipated launches of influenza, flu/COVID combination and Norovirus vaccines-into its oncology and rare disease programs. Investments in late-stage oncology and rare disease programs set the stage for additional growth in 2027 and 2028, with early-stage pipeline investments expected to mature in 2029 and beyond.
Commercial growth drivers include geographic expansion and new product launches. In 2026, the Company expects growth from the annualized impact of long-term partnerships in the UK, Canada and Australia that enhance research and development (R&D) investment, support national security and defense, and provide revenue visibility through onshore manufacturing. The Company also expects continued strong uptake of mNEXSPIKE in the U.S. and its launch in other countries.
In 2027, Europe represents a significant market for respiratory virus vaccines, as a competitor COVID contract lapses and more product approvals are expected. New potential long-term partnerships in Latin America and Asia-Pacific, as well as entry into the flu vaccine market, also position the Company for further expansion.
In 2028, Moderna anticipates a first-to-market flu/COVID combination vaccine and continued momentum with a potential novel Norovirus vaccine, expanding its seasonal franchise to as many as six approved products.
The Company’s existing commercial infrastructure supports these seasonal vaccine growth drivers. A focused Moderna U.S. commercial team engages the same customers across the retail pharmacy, government and healthcare provider (IDN) channels, and teams supporting the UK, Canada and Australia partnerships are established. Additionally, Moderna’s EU commercial infrastructure is in place and targeted investments will be made as needed.
Global Production Network
Since 2022, Moderna has streamlined its production sites into a global manufacturing network ready for new launches and delivering products for multi-year strategic partnerships. The Company exited eight contract manufacturers, announced new drug product capabilities in the U.S., and added three Moderna-built and managed facilities in the UK, Canada and Australia. Increased volume, manufacturing efficiency and waste reduction across Moderna sites is expected to drive a projected 10% improvement in gross margins over the next three years.
In the U.S., Moderna’s facility in Norwood, Massachusetts, enables scalable, end-to-end production by incorporating automation, robotics and AI to increase cost efficiency and reduce waste. The addition of new fill/finish capabilities in 2027 will provide end-to-end control and flexibility with greater speed.
Three new global sites in Laval, Canada; Harwell, UK; and Clayton, Australia enable local access to mRNA medicines and drive revenue diversification. These manufacturing facilities position the Company to deliver cost-optimized growth with margins consistent with U.S. operations.
The Marlborough, Massachusetts, facility was purpose-built for Moderna’s individualized neoantigen therapy, intismeran. Designed for speed and scalability with advanced automation and robotics, the site began clinical batch supply in September 2025 and is on track for commercial launch as the Company methodically right-sizes the intismeran manufacturing process to improve turnaround time and reduce costs.
Pipeline Progress
Highlights from Moderna’s approved vaccines and prioritized portfolio include:
Seasonal Vaccines
Spikevax (mRNA-1273, COVID-19 vaccine): Approved in 40 countries.
mNEXSPIKE (mRNA-1283, COVID-19 vaccine): Approved in the U.S. and Canada. The Company has filed and is targeting 2026 approvals in Australia, the EU, Japan and Taiwan.
mRESVIA (mRNA-1345, RSV vaccine): Approved in 40 countries for adults aged 60 and older, and in 31 of those countries for adults 18-59 at increased risk for RSV disease.
mRNA-1010 (Seasonal Influenza vaccine): Moderna expects to complete submissions for approval of mRNA-1010 in the U.S., EU, Canada and Australia by January 2026.
mRNA-1083 (Seasonal flu + COVID combination vaccine): The Company’s mRNA-1083 filing is under review with the European Medicines Agency (EMA).Moderna submitted for approval to Health Canada in 2025. The Company is awaiting further guidance from the U.S. FDA on refiling.
mRNA-1403 (Norovirus vaccine): The ongoing Phase 3 study has not accrued sufficient cases and is enrolling a second Northern Hemisphere season (2025-2026) for additional case accruals, which will inform the timing of the Phase 3 readout. Moderna expects an interim analysis in 2026.
Oncology Therapeutics
mRNA-4157 (Intismeran autogene): Advancing in collaboration with Merck, with eight Phase 2 and Phase 3 clinical trials underway across multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma.
mRNA-4359 (Cancer antigen therapy): Designed to elicit T-cell immune responses against tumor and immunosuppressive cells, the Phase 1/2 study is ongoing with the Phase 2 portion including cohorts in first-line metastatic melanoma and first-line metastatic NSCLC.
Rare Disease Therapeutics
mRNA-3927 (Propionic Acidemia therapeutic): Reached target enrollment in a registrational study.
mRNA-3705 (Methylmalonic Acidemia therapeutic): Selected for the U.S. FDA’s START program, with a registrational study expected to begin in 2026.
For more details on the data and programmatic updates shared during Moderna’s Analyst Day investor event today, please visit “Events and Presentations” in the Investors section of the Moderna website.
Programs Discontinued
Based on the Company’s strategic prioritization, four programs in its pipeline are discontinued:
mRNA-1647: The Company is discontinuing its congenital Cytomegalovirus (CMV) clinical development program. Moderna will continue to evaluate mRNA-1647 in an ongoing Phase 2 trial of bone marrow transplant patients.
mRNA-1608: The Company’s herpes simplex virus (HSV) clinical development program will not advance to Phase 3.
mRNA-1468: The Company’s Varicella-Zoster virus (VZV) clinical development program will not advance to Phase 3.
mRNA-3745: The Company’s Glycogen Storage Disease Type 1a (GSD1a) clinical development program will not advance to Phase 2.
Financial Updates
Moderna expects up to 10% revenue growth in 2026, driven by the annualized impact of its long-term partnerships with the UK, Canada and Australia and continued strong uptake of mNEXSPIKE in the U.S. and launches in other countries. In addition, the Company has multiple growth opportunities in 2027 and beyond.
The Company is reducing its 2026 and 2027 expected cash costs to approximately $4.2 billion and a range of $3.5 to $3.9 billion, respectively. Moderna will achieve this through disciplined cost management and R&D prioritization, while manufacturing improvements are projected to improve gross margins by more than 10 percentage points over the next three years.
Moderna is increasing its R&D investment allocation in oncology and rare diseases as large infectious disease investments conclude. The Company’s balance sheet sufficiently funds its investments through targeted cash breakeven in 2028.
Today, Moderna announced it has closed a five-year term loan facility for up to $1.5 billion of capital from Ares Management Credit Funds. The non-dilutive financing bolsters the Company’s strong balance sheet and provides increased flexibility. Moderna remains confident in its strong financial framework with enhanced liquidity and today updated its 2025 projected year-end cash and investment balance to a range of $7.1 to $7.6 billion, tied to the $0.6 billion initial loan draw and increased from previous expectations of $6.5 to $7.0 billion.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Spikevax®, mRESVIA® and mNEXSPIKE® are registered trademarks of Moderna.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s anticipated commercial growth drivers, including geographic expansion and new product launches; Moderna’s ability to achieve up to 10% revenue growth in 2026; Moderna’s ability to expand its seasonal vaccine franchise to up to six approved products by 2028; anticipated clinical readouts for Moderna’s oncology pipeline; Moderna’s 2026 and 2027 expected GAAP operating expenses; Moderna’s continued cost management and R&D prioritization and ability to reduce cash costs; Moderna’s balance sheet and targeted cash breakeven in 2028; Moderna’s 2025 projected year-end cash and investment balance; Moderna’s investments in its oncology and rare disease programs; additional growth in 2027-2028; anticipated strong update of mNEXSPIKE in 2026; Moderna’s global production network; the expectation that manufacturing improvements will improve gross margins over the next three years; anticipated regulatory filings and potential approvals; and anticipated milestones for Moderna’s pipeline programs. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.
Assays confirm the Company’s maiden drillhole, RIBN-DD-001, at the RIB North Discovery as the best exploration hole drilled to date at the Angilak Uranium Project;
RIBN-DD-001 assays returned total composite uranium mineralization1 of 34.7 m encompassing seven zones from 287.0 m to 439.9 m (Figure 4) – surpassing what was reported in the release of preliminary results (September 23rd, 2025, News Release);
The widest continuous intersection in the hole – from 426.3 to 439.9 – returned 13.6 m of composite uranium mineralization1 grading 0.53% U3O8, including 1.1 m grading 4.81% U3O8 with the highest-grade sample returning 8.16% U3O8 over 0.5 m;
Mineralization was first intersected in the sandstone over three intervals (between 287.0 m and 351.1 m). The fourth zone was intersected directly above the unconformity (located at 356.7m), extending into graphitic basement rock below. The additional three widest intersections are basement hosted vein style uranium mineralization, associated with strong hematite alteration, graphitic structures and overprinting silicification – similar in style and widths observed in Athabasca Basin basement hosted deposits;
RIB North Discovery is situated along the 4.4 km eastern limb of the Mineralized RIB Corridor (“MRC”) – a 12 km trend containing stacked structural anomalies, identified using 3D EM Inversion modeling. During the 2025 Angilak Exploration Program these anomalies were drill tested, resulting in a 100% success rate of intersecting uranium mineralization, and the discovery of four new mineralized areas: RIB East, West, North and South (Figures 2 & 3);
The nearest drilling to RIBN-DD-001 occurred ~1.4 km along strike at the RIB East Discovery and 1.8 km along strike at the RIB West Discovery areas – both holes intersected uranium mineralization, however, the extension of the structural corridor hosting RIB North mineralization remains untested and highly prospective (Figures 3);
All 2025 mineralized drill core samples have been submitted to the Saskatchewan Research Council (SRC) Geoanalytical Laboratory for analysis. The Company anticipates disclosing all remaining assay results within Q4 2025.
Troy Boisjoli, CEO commented: “During my career as an exploration geologist I have had the pleasure of working in some of the world’s premier regions for discovery of uranium mineralization – such as the Patterson Lake and Rabbit Lake corridors. With that experience, I cannot recall a maiden hole into a target area that returned of an intersection this significant, with assays surpassing our expectations. The grades and thicknesses, the style of mineralization, along with the pathfinder elements and geophysical signatures are all present at the RIB North Discovery. The confirmation of the MRC as an important corridor at the Angilak project – in addition to Lac 50 Deposit Trend, and numerous other showings – reinforces the blue-sky potential that Angikuni Basin could be the next Athabasca Basin. At a time when the Canadian Government is looking to advance mineral resource projects – and strengthen infrastructure in the north. The Angilak Uranium Project is just getting started.”
Cliff Revering, VP Exploration added: “We are extremely pleased with the recently received assay results from RIBN-DD-001, our first drill hole into this target area, which have exceeded the extent and scale of uranium mineralization indicated by our preliminary downhole gamma probe data. Intersecting 34.7 metres of composite uranium mineralization, including a 1.1-metre interval averaging 4.81% U₃O₈, clearly demonstrates the significant scale and high-grade potential present in this zone.
The Mineralized RIB Corridor, anchored by the results of RIBN-DD-001, represents an exciting new discovery along the RIB-Nine Iron Corridor within the Angikuni Basin and reinforces the exploration thesis we have pursued since acquiring the Angilak Project in 2024. Our 2025 drilling, combined with the 3D inversion model from the 2024 MMT survey across the northern Angikuni Basin and Lac 50 Deposit areas, has now identified numerous highly prospective trends and untested targets, positioning us for a compelling 2026 exploration campaign.
Our conviction that the Angikuni Basin is an emerging uranium district with strong potential for additional high-grade uranium discoveries continues to grow as we advance our exploration strategy.”
VANCOUVER, BC / ACCESS Newswire / November 20, 2025 /ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) (“ATHA” or the “Company“), is pleased to announce assay results from the maiden drillhole at the RIB North Discovery, completed as part of the 2025 Angilak Exploration Program at its 100%-owned Angilak Uranium Project in Nunavut, Canada. Assay results from RIBN-DD-001 represent the best exploration hole to date at the Angilak Project, intersecting a total of 34.7 m of composite uranium mineralization1 over seven zones, from 287 m to 439.9 m depth. The highest grade and widest continuous interval of mineralization was intersected from 426.3 to 439.9 m depth, grading 0.53% U3O8 including 8.16% U3O8 over 0.5 m (Figure 4).
The RIB North Discovery is situated along the 4.4 km eastern limb of the Mineralized RIB Corridor (“MRC”) – a 12 km trend containing stacked structural anomalies, identified using 3D EM Inversion modeling. During the 2025 Angilak Exploration Program these anomalies were drill tested, resulting in a 100% success rate of intersecting uranium mineralization, and the discovery of four new mineralized areas: RIB East, West, North and South.
The nearest drilling to RIBN-DD-001 occurred ~1.4 km along strike at the RIB East Discovery area and 1.8 km along strike at the RIB West Discovery area – both holes intersected uranium mineralization, however, the extension of the structural corridor hosting RIB North mineralization remains untested and highly prospective (Figures 1, 2, & 3).
Figure 2: 2025 Angilak Exploration Program – EM Inversion Model & Drill Collar Locations from MRC, along the RIB-Nine Iron Trend.
Figure 3: 2025 Angilak Exploration Program – Isometric schematic of the MRC, displaying EM Inversion model and 2025 drilling.
Table 1: 2025 Angilak Exploration Program Drill Collar Information
Hole ID
Trend
Zone
Azimuth (°)
Dip (°)
Easting (mE)
Northing (mN)
Elevation (m)
Final Depth (m)
*KU-DD-001
RIB-Nine Iron
KU Target
30
70
515830
6936190
256.5
599
*J4R-DD-091
Lac 50
J4/Ray
25
57
522295
6938558
218
650
*RIBE-DD-001
RIB-Nine Iron
RIB East
145
-55
497928
6929449
270
443
*RIBE-DD-002
RIB-Nine Iron
RIB East
145
-55
497766
6929322
271
345
*RIBE-DD-003
RIB-Nine Iron
RIB East
145
-63
497524
6929337
271
398
*RIBE-DD-004
RIB-Nine Iron
RIB East
145
-60
497404
6920180
271
428
*RIBE-DD-005
RIB-Nine Iron
RIB East
155
-65
497530
6929401
270
472
*RIBE-DD-006
RIB-Nine Iron
RIB East
145
-60
497670
6929501
273
491
*RIBE-DD-007
RIB-Nine Iron
RIB East
325
-50
497798
6929101
274
467
*RIBE-DD-008
RIB-Nine Iron
RIB East
325
-55
498284
6929287
264
464
*RIBW-DD-001
RIB-Nine Iron
RIB West
150
-50
495831
6929490
274
503
*RIBW-DD-002
RIB-Nine Iron
RIB West
145
-55
497766
6929322
271
380
*RIBW-DD-003
RIB-Nine Iron
RIB West
325
-55
497645
6930031
275
347
*RIBN-DD-001
RIB-Nine Iron
RIB North
300
-65
499574
6929887
261
623
*RIBS-DD-001
RIB-Nine Iron
RIB South
150
-50
495747
6927640
277.5
377
*KU-DD-002
RIB-Nine Iron
KU Target
30
-70
515525
6936210
251
616
*KU-DD-003
RIB-Nine Iron
KU Target
30
-70
515758
6936059
268.5
56
*KU-DD-003A
RIB-Nine Iron
KU Target
30
-68
515758
6936059
268.5
605
*KU-DD-004
RIB-Nine Iron
KU Target
30
-60
515757
695641
255
602
*KU-DD-005
RIB-Nine Iron
KU Target
210
-70
515980
6935734
256
302
*KU-DD-006
RIB-Nine Iron
KU Target
30
-70
514794
6935805
275
647
*ML-DD-013
Lac 50
ML Target
25
-50
523968
6939404
215
551
*ML-DD-014
Lac 50
ML Target
25
-50
524869
6939109
206
407
*Previously released drillholes from 2025 Angilak Exploration Program
Figure 4: Striplog RIBN-DD-001 showing mineralized interval with composite uranium mineralization1 with average grades – derived from assay samples.
Assay Samples
1.Composite mineralization is calculated using a 0.01% U3O8 cutoff with a maximum internal dilution of 1.5 m.
2The Company considers high-grade mineralization to be any interval over 1% U3O8.
All drill intercepts are core width and true thickness is yet to be determined.
Core samples are submitted to the Saskatchewan Research Council (SRC) Geoanalytical Laboratories in Saskatoon. The SRC facility is ISO/IEC 17025:2005 accredited by the Standards Council of Canada (scope of accreditation #537). The samples are analyzed for a multi-element suite using partial and total digestion inductively coupled plasma methods, for boron by Na2O2 fusion, and for uranium by fluorimetry.
References for Historic Diamond Drilling Results and Surficial Sampling
3For additional information regarding ATHA’s Angilak Project please refer to the Technical Report entitled “Technical Report on the Angilak Property, Nunavut, Canada” with an effective date of October 14, 2025, prepared by Matt Batty, MSc, P. Geo, who is a “qualified person” under NI 43-101, available under ATHA’s SEDAR+ profile at www.sedarplus.ca.
Qualified Person
The scientific and technical information contained in this news release have been reviewed and approved by Cliff Revering, P.Eng., Vice President, Exploration of ATHA, who is a “qualified person” as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects.
About ATHA
ATHA is a Canadian mineral company engaged in the acquisition, exploration, and development of uranium assets in the pursuit of a clean energy future. With a strategically balanced portfolio including three 100%-owned post discovery uranium projects (the Angilak Project located in Nunavut, and CMB Discoveries in Labrador, and the newly discovered basement hosted GMZ high-grade uranium discovery located in the Athabasca Basin). In addition, the Company holds the largest cumulative prospective exploration land package (>7 million acres) in two of the world’s most prominent basins for uranium discoveries – ATHA is well positioned to drive value. ATHA also holds a 10% carried interest in key Athabasca Basin exploration projects operated by NexGen Energy Ltd. and IsoEnergy Ltd. For more information visit www.athaenergy.com.
On Behalf of the Board of Directors
Troy Boisjoli, CEO, ATHA Energy Corp
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These forward-looking statements or information may relate to ATHA’s proposed exploration program, including statements with respect to the expected benefits of ATHA’s proposed exploration program, any results that may be derived from ATHA’s proposed exploration program, the timing, scope, nature, breadth and other information related to ATHA’s proposed exploration program, any results that may be derived from the diversification of ATHA’s portfolio, the prospects of ATHA’s projects, including mineral resources estimates and mineralization of each project, the prospects of ATHA’s business plans and any expectations with respect to defining mineral resources or mineral reserves on any of ATHA’s projects, and any expectation with respect to any permitting, development or other work that may be required to bring any of the projects into development or production.
Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management at the time, are inherently subject to business, market and economic risks, uncertainties and contingencies that may cause actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such assumptions include, but are not limited to, assumptions that the anticipated benefits of ATHA’s proposed exploration program will be realized, that no additional permit or licenses will be required in connection with ATHA’s exploration programs, the ability of ATHA to complete its exploration activities as currently expected and on the current anticipated timelines, including ATHA’s proposed exploration program, that ATHA will be able to execute on its current plans, that ATHA’s proposed explorations will yield results as expected, and that general business and economic conditions will not change in a material adverse manner. Although ATHA has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information.
Such statements represent the current view of ATHA with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by ATHA, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Risks and uncertainties include, but are not limited to the following: inability of ATHA to realize the benefits anticipated from the exploration and drilling targets described herein or elsewhere; in ability of ATHA to complete current exploration plans as presently anticipated or at all; inability for ATHA to economically realize on the benefits, if any, derived from the exploration program; failure to complete business plans as it currently anticipated; overdiversification of ATHA’s portfolio; failure to realize on benefits, if any, of a diversified portfolio; unanticipated changes in market price for ATHA shares; changes to ATHA’s current and future business and exploration plans and the strategic alternatives available thereto; growth prospects and outlook of the business of ATHA; and the ability to advance the Company projects and its proposed exploration program; risks inherent in mineral exploration including risks related worker safety, weather and other natural occurrences, accidents, availability of personnel and equipment, and other factors; aboriginal title; failure to obtain regulatory and permitting approvals; no known mineral resources/reserves; reliance on key management and other personnel; competition; changes in laws and regulations; uninsurable risks; delays in governmental and other approvals, community relations; stock market conditions generally; demand, supply and pricing for uranium; and general economic and political conditions in Canada, Australia and other jurisdictions where ATHA conducts business. Other factors which could materially affect such forward-looking information are described in the filings of ATHA with the Canadian securities regulators which are available on ATHA’s profile on SEDAR+ at www.sedarplus.ca. ATHA does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility
Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash breakeven by 2028
CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it has closed a five-year term loan facility for up to $1.5 billion of capital from Ares Management Credit Funds (Ares), a leading global alternative investment manager, to increase flexibility.
The non-dilutive debt financing consists of three tranches over five years, including:
A $600 million initial term loan funded at closing
A $400 million delayed draw term loan facility (DDTL), available in multiple draws at Moderna’s discretion through November 2027
An additional $500 million DDTL, available in multiple draws at Moderna’s discretion through November 2028. This tranche is contingent on the achievement of key regulatory milestones aligned with Moderna’s late-stage clinical pipeline
“While we remain well-positioned to achieve our 2028 cash breakeven target, this additional capital enhances our strong balance sheet and enables increased flexibility over the coming years,” said Jamey Mock, Chief Financial Officer of Moderna. “Ares is a highly reputable lender in the healthcare space, and we are proud to have their valuable financial backing in pursuit of our long-term financial targets.”
“We are pleased to provide flexible capital to Moderna at this pivotal moment in their growth trajectory,” said Doug Dieter, DrPH, Co-Head of Ares Specialty Healthcare. “Moderna has already demonstrated the power of its mRNA platform with multiple commercial products and has an impressive and differentiated clinical pipeline. This investment reflects Moderna’s disciplined approach to capital management and our support of their long-term financial strategy.”
Moderna will host its Analyst Day event for investors at 9:00 a.m. ET on November 20, 2025. A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Moderna website: https://investors.modernatx.com/. A replay of the webcast will be archived on Moderna’s website for at least 30 days following the presentation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s credit facility with Ares; Moderna’s financial condition and operational flexibility; Moderna’s 2025 financial guidance; Moderna’s 2028 cash breakeven target; and Moderna’s ability to achieve key regulatory milestones aligned with its late-stage pipeline and to draw on future tranches. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.
Nashville, TN November 20, 2025 –(PR.com)– A fourth-generation U.S. Virgin Islander who has called Nashville home since 1993, de Lugo transitioned from an award-winning career in music publishing and feature film producing, with Platinum and Gold Albums, Arista Records A-Team Award, BMI #1 and more, to lavender farming in 2018. Focusing exclusively on Peace Tree Farm’s trademarked, heat- and humidity-tolerant hybrids—Lavender Phenomenal®, Sensational!®, and Exceptional!®—she has proven these cultivars are the definitive choice for Southern growers.
Lloyd Traven, President of Peace Tree Farm, the original breeder of these global-standard varieties, praises de Lugo’s early foresight and influence:
“Over a period of the last decade, Gigi has been highlighting our introductions that have become the Gold Standard for lavender worldwide, and she was an early proponent because she saw the extra value of these introductions… Once she knew the plants were different and far superior, she committed to making the right choice for her customers. She can now proudly say that she has started over 30 new farms on their journey across an area ranging from Virginia through to Iowa!”
From its original rented fields in Whites Creek—Gigi’s Lavender, was celebrated by “Garden & Gun” magazine as one of the South’s top lavender destinations—the licensed nursery has supplied thousands of Peace Tree-bred plants throughout Tennessee and beyond. In 2019, de Lugo founded “The Lavender Exchange (TLx),” an exclusive membership alliance offering ongoing technical support, resource sharing, cooperative marketing, and agritourism promotion to farms that source their plants exclusively from Gigi’s Nursery.
Traven also highlights the impact of this network: “Gigi also knows the great importance and value of marketing with expression of clear benefits and a clear message. She created the Lavender Exchange with this in mind—to provide an outlet for cooperative marketing and sharing of equipment and machinery and product ideas.”
This strengthened ownership ensures continuity for de Lugo’s research, educational outreach, and product innovation at the Joelton location, including her newest Patent Pending offering, “ZWave Mg”—a topical magnesium spray infused with pure Phenomenal lavender hydrosol steam-distilled exclusively from flowers grown by TLx member farms. Designed for relaxation, muscle relief, and better sleep, ZWave Mg showcases the wellness potential of Southern-grown lavender.
“This milestone gives us the stability and security to continue investing in our Southern lavender research, development, product distribution, and growing community of the farms we support through The Lavender Exchange (TLx),” said Gigi de Lugo. “From the beginning I set out to prove lavender could become a viable cash crop for Tennessee and Southern farms—not only a pretty agritourism field, but a real harvestable commodity built on Phenomenal®. It took courageous pioneers willing to bet on the unproven and stay the course with me. These years, alongside the extraordinary farmers of our TLx family, have been one of the greatest adventures of my life.”
Experience the pure essence of Southern lavender: Gigi’s premium products, including the breakthrough ZWave Mg, are available exclusively through her website, and retail partners across Tennessee. Gigi is in discussion with a Nashville based manufacturer to expand her ZWave Mg production capacity for 2026.
About Gigi’s Lavender Nursery & Farm
Gigi’s Lavender Nursery & Farm is a Tennessee-licensed grower and an exclusive Southeast source for Peace Tree Farm’s Phenomenal®, Sensational!®, Exceptional!®, Inspirational!® lavender cultivars. It serves as headquarters for The Lavender Exchange (TLx), a premier network advancing lavender agriculture and agritourism across the South and Midwest.
Contact Information:
TLx The Lavender Exchange
Gigi de Lugo
615-422-5083 Contact via Email
thelavenderexchange.com
Office: 615-422-5083
TAMPA, FL / ACCESS Newswire / November 20, 2025 / Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a health information technology leader at the nexus of serialization of healthcare technology infrastructure into the individual patient fulfillment of prescription drug through pharmacies ‘From Manufacturer To Patient’, today reported financial results for the period ended September 30, 2025 on Form 10-Q on November 19, 2025[1] and provided a business update from the CEO.
“The last 6 weeks have really allowed me to understand the different stages of development of the various parts of the business after I was reappointed as President and given the title of Interim-CEO on October 6, 2025,” said Prashant Patel, RPh, President and Interim-CEO of Wellgistics Health. “We have centered the primary focus of our sales team on the launch of Brenzavvy® for the Type 2 diabetes market. Type 2 diabetes affects over 33 million Americans[2] with only a small portion of patients getting access a SGLT-2 inhibitor drug primarily to out-of-pocket cost constraints. We have developed a program to significantly reduce these out-of-pocket costs for patients using our EinsteinRx™ AI pharmacy hub software, and expect this product launch may contribute meaningfully to our future revenue growth if successfully commercialized. One of the brightest spots in my review has been the tremendous work done over the last 6 months by our technology team led by Chief Technology Officer Srini Kalla to finalize EinsteinRx and make it ready for launch. The ability of our tech team to help implement our software seamlessly for our clients will be crucial for our long-term success and I now have great confidence in Srini’s ability to meet the growth challenge we expect to face.”
Mr. Patel continued, “While the third quarter saw significant equity-based expenses tied to the pre-IPO acquisition of our pharmaceutical distribution business unit, we have begun to rationalize our go forward approach and it will be centered on the staged integration of EinsteinRx throughout our customers’ value chains. As we prepare to move into 2026 when we intend to put EinsteinRx onto the PharmcyChain™ smart contracts platform we expect to create, we believe there is a meaningful opportunity to optimize the way healthcare information is processed, exchanged and validated. By giving us better data to feed into our models, we intend to further optimize outcomes for patients while delivering cost reduction for payers. We are in advanced discussions to to complete the license agreement underpinning our blockchain smart contracts strategy with DataVault AI (NASDAQ:DVLT) in the fourth quarter of 2025 or the first quarter of 2026 in order to secure the opportunity-enabling intellectual property protection around which we will execute upon our roadmap to disrupt healthcare through efficiency.”
“In order to create a competitive edge in our GLP-1 offering business to pharmacies and telehealth companies, in March we partnered with Tollo Health to provide prescription-complementary products to address major GLP-1 side effects with their products soon becoming commercially available in the United States. The GLP-1 drug market currently sits at $53 billion annually according to Grandview Research and expected to reach $156 billion by 2030[6], currently dominated by Eli Lilly and Novo Nordisk, with various injection and oral formulations that all carry muscle loss side effects. Our goal is to eventually offer all GLP-1 drugs to pharmacy clients and through our online pharmacy at competitive prices, while selling cash-pay side effect-mitigating medical foods that we believe provide a more comprehensive solution than our competitors, while increasing margins per GLP-1 prescription.”
“We expect our first GLP-1 side effect product that helps to mitigate muscle loss will launch in the first quarter of 2026. Additionally, we have begun distributing 3CL protease inhibitor cleansing supplement Tollovid™ targeting Long COVID to certain physicians. In 2024, the CDC reported that over 17 million Americans were living with Long COVID[7]. We expect certain Long COVID clinicians to begin making Tollovid available for their patients this month. We also plan to launch the first natural antiviral combo Tollovid and Galectovid™ to pharmacies after Thanksgiving. We intend to expand our prescription drug catalog to include drugs frequently prescribed for Long COVID in order to develop a full package for pharmacies.”
Mr. Patel completed, “Lastly, the previously disclosed acquisition of Peek Healthcare Technologies, Inc. has been terminated as it is no longer strategically aligns with our plans for the future.”
Financial Results The Company recorded a net operating loss of $33.878 million in the third quarter of 2025, compared with a net operating loss of $1.867 million in the third quarter of 2024. The increase in net loss was largely due to increased stock-based compensation. Net loss per share in the third quarter of 2025 was $0.46 on 74.379 million weighted average shares outstanding, compared to third quarter of 2024 where the Company delivered a net loss of $0.04 per share on 48.403 million weighted average shares outstanding.
About Wellgistics Health, Inc. Wellgistics Health (NASDAQ:WGRX) is pharmacy physical and technology enabling health IT company that specializes in optimizing the delivery medications from manufacturers to patients. Its integrated platform connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.
Forward-Looking Statements This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.
Investor Relations Contact Skyline Corporate Communications Group, LLC Scott Powell, President 1177 Avenue of the Americas, 5th Floor New York, NY 10036 Office: (646) 893-5835 Email: info@skylineccg.com
